Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1991-2-14
|
pubmed:abstractText |
The role of granulocyte-macrophage colony-stimulating factor (GM-CSF) in the growth of multiple myeloma (MM) was investigated in 21 patients with MM. In 17 patients with proliferating myeloma cells in vivo, recombinant GM-CSF significantly increased the endogenous-IL-6-mediated spontaneous myeloma cell proliferation occurring in 5-day cultures of tumor cells in vitro (P less than .01). Furthermore, GM-CSF was detected in 5-day culture supernatants of myeloma bone marrow cells. This endogenous GM-CSF was produced by the myeloma bone marrow microenvironment but not by myeloma cells and contributed to the spontaneous myeloma-cell proliferation observed in 5-day cultures. In fact, this proliferation was partially blocked (67%) by anti-GM-CSF monoclonal antibodies. The stimulatory effect of rGM-CSF was mediated through IL-6 because it was abrogated by anti-IL-6 monoclonal antibodies. rGM-CSF did not reproducibly increase the endogenous IL-6 production in short-term cultures of bone marrow cells of MM patients. Using an IL-6-dependent myeloma cell line (XG-1 cell line), rGM-CSF was shown to act directly on myeloma cells stimulating by twofold their IL-6 responsiveness. rGM-CSF did not induce any IL-6 production in XG-1 cells, nor was it able to sustain their growth alone. Although no detectable GM-CSF levels were found in the peripheral or bone marrow blood of MM patients, it is possible that GM-CSF, produced locally by the tumoral environment, enhances the IL-6 responsiveness of myeloma cells in vivo in a way similar to that reported here in vitro.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
76
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2599-605
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2265252-Aged,
pubmed-meshheading:2265252-Aged, 80 and over,
pubmed-meshheading:2265252-Antibodies, Monoclonal,
pubmed-meshheading:2265252-Bone Marrow,
pubmed-meshheading:2265252-Bone Marrow Cells,
pubmed-meshheading:2265252-Cell Division,
pubmed-meshheading:2265252-Drug Synergism,
pubmed-meshheading:2265252-Female,
pubmed-meshheading:2265252-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:2265252-Humans,
pubmed-meshheading:2265252-Interleukin-6,
pubmed-meshheading:2265252-Male,
pubmed-meshheading:2265252-Middle Aged,
pubmed-meshheading:2265252-Multiple Myeloma,
pubmed-meshheading:2265252-Recombinant Proteins,
pubmed-meshheading:2265252-Tumor Cells, Cultured
|
pubmed:year |
1990
|
pubmed:articleTitle |
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells.
|
pubmed:affiliation |
Institut National de la Santé et de la Recherche Médicale, Montpellier, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|